We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

78 hedge funds and large institutions have $50.5M invested in Cue Biopharma in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 23 increasing their positions, 9 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

428% more call options, than puts

Call options by funds: $586K | Put options by funds: $111K

156% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 9

123% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 13

24% more funds holding

Funds holding: 63 → 78 (+15)

17% more capital invested

Capital invested by funds: $43M → $50.5M (+$7.51M)

0.14% more ownership

Funds ownership: 0.93% → 1.07% (+0.14%)

Holders
78
Holders Change
+15
Holders Change %
+23.81%
% of All Funds
1.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
29
Increased
23
Reduced
9
Closed
13
Calls
$586K
Puts
$111K
Net Calls
+$475K
Net Calls Change
+$371K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$5.49M
2
State Street
State Street
Massachusetts
+$2M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.55M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.08M
5
Northern Trust
Northern Trust
Illinois
+$992K

Top Sellers

Rank Fund Capital Flow
1
PM
Prosight Management
Texas
-$4.11M
2
Millennium Management
Millennium Management
New York
-$653K
3
PAWC
P.A.W. Capital
Connecticut
-$536K
4
CC
Carlson Capital
Texas
-$470K
5
VC
Voss Capital
Texas
-$446K
Name Holding Trade Value Shares
Change 		Change in
Stake
SPC
1
Slate Path Capital
New York
$8.77M – – –
BlackRock
2
BlackRock
New York
$7.54M +$5.49M +46,721 +211%
Vanguard Group
3
Vanguard Group
Pennsylvania
$7.48M +$1.55M +13,164 +24%
BL
4
Bleichroeder LP
New York
$2.76M – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$2.66M +$1.08M +9,223 +61%
State Street
6
State Street
Massachusetts
$2.38M +$2M +17,005 +361%
Dimensional Fund Advisors
7
Dimensional Fund Advisors
Texas
$2.03M +$37.7K +321 +2%
RSWM
8
Robertson Stephens Wealth Management
California
$1.75M – – –
SCM
9
Silverarc Capital Management
Massachusetts
$1.47M +$381K +3,238 +32%
MAM
10
Monaco Asset Management
Monaco
$1.35M -$376K -3,198 -21%
Northern Trust
11
Northern Trust
Illinois
$1.21M +$992K +8,438 +323%
AR
12
Advisory Research
Illinois
$939K – – –
SPC
13
Sigma Planning Corp
Michigan
$822K +$17.3K +147 +2%
Millennium Management
14
Millennium Management
New York
$649K -$653K -5,559 -48%
Renaissance Technologies
15
Renaissance Technologies
New York
$566K +$407K +3,464 +203%
Bank of America
16
Bank of America
North Carolina
$559K -$56.1K -477 -9%
Stifel Financial
17
Stifel Financial
Missouri
$538K +$3.41K +29 +0.6%
N
18
Nuveen
North Carolina
$534K +$573K +4,878 New
CC
19
Carlson Capital
Texas
$489K -$470K -4,000 -47%
Morgan Stanley
20
Morgan Stanley
New York
$386K +$26.9K +229 +7%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$377K +$321K +2,728 +384%
Citadel Advisors
22
Citadel Advisors
Florida
$362K -$25.4K -216 -6%
Charles Schwab
23
Charles Schwab
California
$351K +$274K +2,334 +269%
UBS Group
24
UBS Group
Switzerland
$293K +$87.3K +743 +38%
HighTower Advisors
25
HighTower Advisors
Illinois
$278K – – –
1
2 3 4

CUE Hedge Fund Activity: Q2 2023 in Review

78 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q2 2023, worth a combined $50.5M — up 17% from $43M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new CUE positions and 13 closed out — a net gain of 16 holders — while 23 added to existing stakes and 9 trimmed.

The largest buyer was BlackRock, adding an estimated $5.49M. The largest seller was Prosight Management, exiting entirely with an estimated $4.11M sold.

  • 78 institutional investors held Cue Biopharma (CUE) as of Q2 2023, up from 63 in Q1 2023.
  • Funds reported $50.5M of Cue Biopharma stock for Q2 2023, up 17% quarter-over-quarter.
  • 29 funds opened new Cue Biopharma positions in Q2 2023 and 13 closed out, a net change of +16 holders.
  • The largest Cue Biopharma buyer in Q2 2023 was BlackRock, an estimated $5.49M added.
  • The largest Cue Biopharma seller in Q2 2023 was Prosight Management, an estimated $4.11M sold.

Based on aggregated 13F filings for Q2 2023.